A B S T R A C T Intravenously infused L-dopa (0.3 mg/ kg per min) produced hypertension and cardiac arrhythmias in halothane anesthetized dogs. Biochemical studies showed that the heart, kidney, and brain of these animals accumulated significant amounts of catecholamines formed from the administered precursor.
The pressor response to intravenous injections of norepinephrine and dopamine was unchanged. Hindlimb arterial pressure response to direct electrical stimulation of the lumbar sympathetic trunk was also unchanged.
Pretreatment with a drug which inhibits brain as well as extracerebral dopa decarboxylase [D,L-seryl-2,3,4-trihydroxybenzylhydrazine hydrochloride] abolished all effects of L-dopa on blood pressure. In these animals, there was a marked reduction of catecholamine formation from L-dopa in the brain as well as the heart and kidney.
INTRODUCTION
As treatment of Parkinson's syndrome with L-dopa has become more prevalent, cardiovascular side effects have been observed with increasing frequency. Hypertension and cardiac arrhythmias, effects which may reflect the presence of excessive amounts of catecholamines, have been observed in some patients receiving L-dopa (1) (2) (3) .
Much more common, however, has been the development of hypotension in patients receiving this therapy (1, 2, 4) . The mechanism by which L-dopa may produce hypertension in some patients and a paradoxical depressor effect in other patients is unclear.
The present study was performed to directly examine some cardiovascular effects of L-dopa in anesthetized dogs. We have given L-dopa alone as well as after pretreatment with decarboxylase inhibitors, and we have attempted to correlate the rate of formation of catecholamines in heart, kidney, and brain with the effects of L-dopa on blood pressure. The rate of decarboxylation of L-dopa was altered by administration of an inhibitor of decarboxylase which does not readily penetrate the bloodbrain barrier, MK 485 [DL-a-hydrazino-a-methyl-#- (3, The Journal of Clinical Investigation Volume 50 1971 dihydroxyphenyl) propionic acid]1 (5) , and one which has been reported to be an effective inhibitor of both peripheral and brain decarboxylase, L-dopa2 was dissolved in physiological saline, adjusted to pH 2.0 with hydrochloric acid, and delivered at a constant rate through a continuous infusion pump (Harvard Apparatus Co, Millis, Mass.). Blood pressure responses to varying doses of L-dopa were determined by administering doses, in random sequence, ranging between 0.0001 and 0.3 mg/kg per min. If a pressor effect was observed, the blood pressure was allowed to return to baseline levels before another dose was given. In all other experiments L-dopa was administered at a rate of 0.3 mg/kg per min. MK 485 3 (50 mg/kg administered intravenously over a 15 min interval) or RO 44602 4 (100 mg/kg administered intravenously over a 45 min interval) were given at the times indicated in Results.
Other cardiovascular studies. In all these experiments, dogs were pretreated with MK 485 (50 mg/kg) and given i.-dopa at a rate of 0.3 mg/kg per min. Changes in peripheral resistance in an isolated vascular bed were studied by perfusing the left hindlimb with blood obtained from the aorta and pumped through a peristaltic pump (Sigmamotor Inc, Middleport, N. Y.) into a cannula placed in the left external iliac artery. To eliminate significant collateral flow, the aorta below the origin of the internal iliac arteries, the inferior mesenteric artery, and three pairs of lower lumbar arteries were ligated. The peristaltic pump was calibrated to deliver blood to the hindlimb at rates ranging from 34 to 260 ml/min. The left lumbar sympathetic trunk 'Abbreviations used in this paper: MK 485, D,L-a-hydrazino-a-methyl-,8- (3,4- (6) .
Statistical significance of differences between means was evaluated by t tests (7) . (Fig. 3) . All several flow rates, in hindlimb perfusion pressure (Fig.  4) . This apparent decrease in peripheral resistance paralleled the decrease in systemic blood pressure. Cardiac output in five dogs was not significantly changed by MK 485 followed by L-dopa infusion for 1 hr, although blood pressure in these animals fell markedly (Fig. 5) . Effect of MK 485 followed by L-dopa infusion on sympathetic neuronal function. In six dogs, the central aortic and hindlimb perfusion pressure responses to the injection of norepinephrine was not significantly changed by MK 485 followed by infusion of L-dopa at a rate of 0.3 mg/kg per min for about 1 hr (Fig. 6) . Likewise, the pressor response in the aorta and hindlimb to the injection of dopamine was unchanged in three dogs (Fig.  7) . The increase in hindlimb perfusion pressure in response to direct electrical stimulation of the lumbar sympathetic nerve was also unchanged by MK 485 followed by 1 hr of L-dopa infusion in three dogs (Fig. 8) .
RESULTS

Effect of L-dopa
In all these experiments, the mean arterial pressure was significantly lowered by the combination treatment of MK 485 and L-dopa.
In seven dogs, the increase in aortic pressure with bilateral carotid occlusion was 39.7 ±8.5 mm Hg before L-dopa treatment and 18.6 ±9.8 mm Hg (P < 0.001) after 1 hr of L-dopa infusion in MK 485 pretreated dogs. After L-dopa treatment, the mean arterial pressure in most of these dogs was about 60 mm Hg compared to a baseline value of about 95 mm Hg. Prochnik and Stutzman demonstrated that the pressor response to bilateral carotid occlusion is directly related to the mean blood pressure existing when the reflex is evoked (8) . Analysis of our data according to a formula suggested by him, revealed that the reduction in baroreceptor response that we observed could be entirely due to the pronounced hypotension produced in these animals. Effect of decarboxylase inhibitors on formation of catecholamines from L-dopa-H'. In six dogs which had received L-dopa (0.3 mg/kg per min) labeled with tritiated L-dopa (2.5 or 5.0 /Ci/mg) there was the expected elevation of blood pressure at the end of 30 min of infusion. At this time, the hearts, kidneys, and brains of these animals had accumulated significant amounts of catecholamines which had been formed from the tritiated precursor (Table I) . Six dogs pretreated with MK 485 had a marked reduction in levels of tritiated catecholamines in the hearts and kidneys, but no significant change in the brains. These animals had a decrease in blood pressure. In six dogs pretreated with RO 4-4602 there was a significant decrease in tritiated catecholamine content in the brains as well as the hearts and kidneys. No change in blood pressure was apparent in animals pretreated with RO 4-4602. cal studies showed that significant amounts of catecholamines formed from L-dopa had accumulated in extracerebral organs. The development of hypertension was probably a consequence of the formation of catecholamines (dopamine and norepinephrine) by decarboxylation of L-dopa. Dopamine stimulates beta-adrenergic receptors of the myocardium (9) and beta or alpha adrenergic receptors of the vascular beds of dogs (10) . With large enough doses of dopamine, stimulation of alpha receptors predominates and peripheral vascular resistance is increased. This combined with increased cardiac output produces a pressor response (11) . The cardiovascular effects of norepinephrine are well-known (12) . The arrhythmias observed were probably also secondary to the accumulation of catecholamines in the heart in the presence of halothane anesthesia. Haloge-AORTIC HINDLIMB nated hydrocarbons are known to potentiate the arrhythmogenic effects of catecholamines (13) . Pretreatment with MK 485 markedly reduced catecholamine formation from tritium-labeled L-dopa in the heart and kidney, but not in brain. This was expected since this drug does not readily penetrate the bloodbrain barrier (5) . The block in decarboxylation of L-dopa in extracerebral organs appeared to prevent the development of hypertension and hypotension became apparent. The peripheral decarboxylase inhibitor was also effective in preventing or reversing the arrhythmias which developed during infusion of L-dopa.
The cardiac output and hindlimb perfusion studies demonstrated that the hypotension caused by L-dopa after MK 485 pretreatment was secondary to a reduction in peripheral resistance of vascular beds. Pressure in the perfused hindlimb fell even though flow was maintained and cardiac output was unchanged by this treatment. This reduction in peripheral resistance was not associated with any change in adrenergic nerve or receptor function. The blood pressure response to intravenous norepinephrine, dopamine, or nerve stimulation was not altered.
Low doses of dopamine lower blood pressure in anesthetized dogs by selectively dilating certain vascular beds (10 (16) . It has also been shown that concentrations of norepinephrine in lower brainstem and hypothalamus of genetically hypertensive rats is lower than in control rats (17) . Administration of L-dopa with MK 485, which may increase the levels of norepinephrine in these areas of brain, appears to lower the blood pressure of these rats (17) .
In another recently published study, Whitsett, Halushka, and Goldberg showed that L-dopa impairs the function of postganglionic sympathetic nerves in dogs (18) . This produces an attenuation of the carotid-occlusion baroreceptor reflex and the rise in femoral vascular resistance in response to sympathetic nerve stimulation. This action of L-dopa appears to be dependent on decarboxylation of L-dopa in peripheral tissues, as RO 4-4602 in a dose of 50 mg/kg abolishes this effect (18) .
A decarboxylated product of L-dopa thus appears to pro-duce a direct inhibitory effect on sympathetic nerves in dogs. This peripheral effect many contribute to the hypotensive action of L-dopa. The results of the present study would suggest, however, that the hypotensive action of L-dopa is not dependent on this peripheral effect of its decarboxylated product. Hypotension occurred when peripheral decarboxylase was inhibited and while adrenergic neuronal function was not impaired.
The findings of the present study may provide some insight into the mechanism by which L-dopa produces cardiovascular effects in patients. Some patients may be either more sensitive to catecholamines or, because of differences in metabolism of administered L-dopa, accumulate catecholamines in extracerebral tissues. These patients may therefore develop hypertension or cardiac arrhythmias when treated with large doses of L-dopa. More commonly, cardiovascular effects suggesting the presence of excessive amounts of peripheral catecholamines are not apparent. Rather, patients became hypotensive. Hypotension is especially marked in the standing position but recumbent blood pressure also appears to be lowered (4, 19) . Furthermore, inhibition of extracerebral decarboxylase appears to potentiate the hypotensive effect of L-dopa (19) . In these patients, hypotension may be secondary to the accumulation of catecholamines in the central nervous system.
